Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(6 sites)

United States

University of Miami, Miami, Florida

Weill Cornell Medical College, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Vanderbilt University Medical Center, Nashville, Tennessee

UT Southwestern Medical Center at Dallas, Dallas, Texas